Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation
- PMID: 21484835
- DOI: 10.1002/mus.22092
Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation
Abstract
The objective of this report was to develop a scientifically sound and clinically relevant evidence-based guideline for the treatment of painful diabetic neuropathy (PDN). The basic question that was asked was: "What is the efficacy of a given treatment (pharmacological: anticonvulsants, antidepressants, opioids, others; non-pharmacological: electrical stimulation, magnetic field treatment, low-intensity laser treatment, Reiki massage, others) to reduce pain and improve physical function and quality of life (QOL) in patients with PDN?" A systematic review of literature from 1960 to August 2008 was performed, and studies were classified according to the American Academy of Neurology classification of evidence scheme for a therapeutic article. Recommendations were linked to the strength of the evidence. The results indicate that pregabalin is established as effective and should be offered for relief of PDN (Level A). Venlafaxine, duloxetine, amitriptyline, gabapentin, valproate, opioids (morphine sulfate, tramadol, and oxycodone controlled-release), and capsaicin are probably effective and should be considered for treatment of PDN (Level B). Other treatments have less robust evidence, or the evidence is negative. Effective treatments for PDN are available, but many have side effects that limit their usefulness. Few studies have sufficient information on their effects on function and QOL.
Copyright © 2011 Wiley Periodicals, Inc.
Similar articles
-
Evidence-based guideline: Treatment of painful diabetic neuropathy [RETIRED]: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.Neurology. 2011 May 17;76(20):1758-65. doi: 10.1212/WNL.0b013e3182166ebe. Epub 2011 Apr 11. Neurology. 2011. PMID: 21482920 Free PMC article.
-
Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.PM R. 2011 Apr;3(4):345-52, 352.e1-21. doi: 10.1016/j.pmrj.2011.03.008. PM R. 2011. PMID: 21497321
-
Treatments for diabetic neuropathy.J Peripher Nerv Syst. 2012 May;17 Suppl 2:22-7. doi: 10.1111/j.1529-8027.2012.00391.x. J Peripher Nerv Syst. 2012. PMID: 22548619 Review.
-
The effect of exercise therapy combined with psychological therapy on physical activity and quality of life in patients with painful diabetic neuropathy: a systematic review.Scand J Pain. 2019 Jul 26;19(3):433-439. doi: 10.1515/sjpain-2019-0001. Scand J Pain. 2019. PMID: 31112511
-
An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy.J Diabetes Res. 2022 Jan 27;2022:9989272. doi: 10.1155/2022/9989272. eCollection 2022. J Diabetes Res. 2022. PMID: 35127954 Free PMC article. Review.
Cited by
-
The Last Decade Publications on Diabetic Peripheral Neuropathic Pain: A Bibliometric Analysis.Front Mol Neurosci. 2022 Apr 13;15:854000. doi: 10.3389/fnmol.2022.854000. eCollection 2022. Front Mol Neurosci. 2022. PMID: 35493329 Free PMC article.
-
Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions.Int Clin Psychopharmacol. 2014 Jul;29(4):206-11. doi: 10.1097/YIC.0000000000000025. Int Clin Psychopharmacol. 2014. PMID: 24374906 Free PMC article.
-
Diabetic neuropathy and the sensory neuron: New aspects of pathogenesis and their treatment implications.J Diabetes Investig. 2018 Nov;9(6):1239-1254. doi: 10.1111/jdi.12833. Epub 2018 Apr 25. J Diabetes Investig. 2018. PMID: 29533535 Free PMC article. Review.
-
An Assessment of Clinically Important Differences on the Worst Pain Severity Item of the Modified Brief Pain Inventory in Patients with Diabetic Peripheral Neuropathic Pain.Pain Res Manag. 2018 Jul 22;2018:2140420. doi: 10.1155/2018/2140420. eCollection 2018. Pain Res Manag. 2018. PMID: 30140328 Free PMC article. Clinical Trial.
-
Beyond p-values: a cross-sectional umbrella review of chemotherapy-induced peripheral neuropathy treatments.Front Pain Res (Lausanne). 2025 Mar 19;6:1564662. doi: 10.3389/fpain.2025.1564662. eCollection 2025. Front Pain Res (Lausanne). 2025. PMID: 40176845 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical